Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, commemorated its 50-year anniversary by awarding $150,000 in total grants to three organizations that share its goal to improve healthcare: The American Red Cross, the National Ovarian Cancer Coalition and Autism Speaks.
At a ceremony at the company’s flagship clinical laboratory in Teterboro, NJ, the company’s chairman, president and CEO Steve Rusckowski presented Health In Your Hands grants of $50,000 to representatives from each organization. Paul Brown, M.D., founder and former CEO of Quest’s predecessor company Metropolitan Pathology Laboratory, Inc. or MetPath, established in April, 1967, was also recognized at the event.
To view the multimedia release go to:
https://www.multivu.com/players/English/8080751-quest-diagnostics-50th-anniversary/
Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the COMPACT study, a pivotal Phase III study evaluating the safety and efficacy of CSL830 (a novel, investigational, self-administered, subcutaneous C1-Esterase Inhibitor [C1-INH] Human replacement therapy) for the prevention of HAE attacks. The study met its primary efficacy endpoint, significantly reducing the time-normalized number of HAE attacks. In addition, the study met its secondary endpoints, including the responder rate (patients who had at least a 50% reduction in their attack rate) and the number of rescue medication uses. If approved by the FDA, CSL830 would be the first and only subcutaneous preventative therapy for HAE.
To view the multimedia release go to:
https://www.multivu.com/players/English/8056151-csl-behring-subcutaneous-c1-esterase-inhibitor-hae-patients/
St. Jude Children’s Research Hospital is naming the institution’s principal research tower after Donald Pinkel, M.D., whose legacy of driving progress toward advancing cures for pediatric catastrophic diseases continues at the institution today.
When St. Jude was established 55 years ago, Pinkel, the hospital’s first medical director, committed to finding cures for childhood cancer, leading to groundbreaking treatments that saved countless children’s lives. Many of these cancers were deemed incurable prior to Pinkel’s research, but his distinct approach to eradicating diseases established a model for how cancers could be treated.
To view the multimedia release go to:
https://www.multivu.com/players/English/7924752-st-jude-childrens-research-hospital-donald-pinkel-tower/
Sanofi Consumer Healthcare – the makers of new Xyzal® Allergy 24HR, which is now available on retail shelves nationwide – revealed today the results of a social experiment in which 160 participants (80 allergy sufferers and 80 non-sufferers) wore a wearable device for 30 days to track their sleep and activity. The first-of-its-kind experiment found allergy symptoms can impact various elements of sufferers’ lives, including both the quality of their sleep and their daytime activities. Xyzal is partnering with renowned allergist Dr. Neeta Ogden to encourage allergy sufferers to Wise Up about the importance of managing their allergies this spring, so they can have a better night’s sleep and Rise Up in the morning to take on the day.
To view the multimedia release go to:
https://www.multivu.com/players/English/8029451-sanofi-xyzal-allergy-social-experiment-wise-up-rise-up/
GSK Consumer Healthcare and FLONASE® Sensimist™ Allergy Relief, along with Emmy® Award-winning choreographer and entertainer Derek Hough, today announced the launch of the 2017 Greater American Road Trip featuring social media’s favorite family, the Eh Bees. On Thursday, March 16, the Eh Bee family will begin their coast-to-coast journey to rethink allergy treatment and leave each city a little bit greater than they found it.
Derek, along with Eh Bee family members Mama Bee and her son Mr. Monkey, all suffer from allergies, but are determined to be greater than their itchy, watery eyesi and congested noses with the help of new FLONASE Sensimist. After kicking off the journey together in Los Angeles, Derek will challenge the Eh Bees and their allergies as they partner with local organizations throughout some of the worst allergy cities in the country.
To view the multimedia release go to:
https://www.multivu.com/players/English/8061451-flonase-greater-american-road-trip-derek-hough-eh-bee/
See America, Allergan’s initiative to fight against preventable blindness in the United States, today unveiled a powerful video featuring award-winning actor and hip-hop artist Common, that urges Americans to “stand in the way of darkness”.
The video harnesses Common’s striking spoken word ability, calling on Americans to fight against vision loss and prioritize their vision. Common highlights the 61 million Americans at-risk of severe vision loss, and challenges us all to imagine a life without sight.
“I'm proud to join Allergan in the fight against preventable blindness,” said Common. “Sight is something that far too many of us take for granted. I hope our message resonates with people across the country, no matter what age or background.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8057551-common-joins-allergan-see-america-against-preventable-blindness/
Today on Rare Disease Day, My Life, Our Future, a national program founded by leaders in the bleeding disorder community, including Bloodworks Northwest, the American Thrombosis and Hemostasis Network, the National Hemophilia Foundation and Bioverativ Inc., opened the largest research repository of its kind in the world to scientists. The My Life, Our Future Research Repository is a collection of genetic data and blood samples that are linked to phenotypic data from more than 5,000 people in the U.S. with hemophilia, a rare disorder that impairs the ability of one’s blood to clot. The My Life, Our Future Research Repository will allow researchers to advance the scientific understanding of the disorder, including genetic differences that affect bleeding severity and reaction to certain treatments.
To view the multimedia release go to:
https://www.multivu.com/players/English/8046151-national-hemophilia-foundation-my-life-our-future/
E-Alternative Solutions (EAS), a sister company to Jacksonville-based Swisher International, today launched a national advertising campaign for the Cue™ Vapor System (Cue) (patent pending), a breakthrough alternative to smoking. Cue is vaping made simple, providing fulfilling satisfaction in a premium-performance, stylish device that any adult smoker can operate with just the click of a cartridge and the push of a button. The closed system enables consumers to sidestep the complicated, and sometimes messy, process of using typical vaping devices. Cue is available for purchase online with appropriate age verification by visiting www.cuevapor.com.
To view the multimedia release go to:
https://www.multivu.com/players/English/8038851-e-alternative-solutions-eas-cue-vapor-system/
Imagine trying to make a decision with only half the information. Today, nearly all organizations across the public and private sectors rely on data to make better decisions about everything from employee salaries to new legislation. Data provides decision makers insight into what the baseline is, where collective needs are, and where resources should be allocated. But half our world’s population—women—are underrepresented and many times completely unrepresented in these datasets.
Inaccurate data often results from gender bias in the design of surveys or questionnaires, or from someone other than the woman or girl responding to a survey on her behalf. Misrepresented or incomplete gender data collection yields results that misses the mark on understanding women’s needs or their economic and social contributions. Policies and initiatives around healthcare, education, economic opportunity and more are built based on what’s available—gender-biased data—and fail to fairly serve women and girls. How can we close the gender data gap and pursue the global ambition towards gender equality and a fuller understanding of the whole population?
To view the multimedia release go to:
http://www.multivu.com/players/English/7889731-bloomberg-western-digital-bgovdata/
St. Catherine Hospital from Croatia has been named as one of the finalists, and Ruban d’Honneur recipients, in the 2016/17 European Business Awards sponsored by RSM.
It is one of only 110 finalists announced after over 33,000 businesses were engaged in the competition, and was chosen by a panel of independent judges because it displayed the core values of innovation, ethics and success.
The company will now undertake an in depth face-to-face interview, and will find out if it is a winner of one of the 11 categories at a Gala Final on May 4 in Dubrovnik.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8037951-st-catherine-hospital-business-awards/
Visionworks and Davis Vision kicked off 2017 continuing their work to raise awareness about the importance of annual eye exams for school-aged children by increasing the number of vouchers and glasses they will donate this school year from 10,000 to 15,000. Through their joint initiative, Let’s Go See has already donated more than 8,300 vouchers since the 2016-17 school year started.
“The Let's Go See program has been instrumental in our efforts to spread awareness of the need for annual eye exams for school-aged children. We feel honored to help families provide eye exams and glasses to their kids, and look forward to continuing our mission,” said Jim Eisen, president and CEO of HVHC Inc., and president of Visionworks.
Between dental checkups, doctor's exams, and everything else parents do to keep kids healthy, children’s vision often gets overlooked. Many parents wait until their child has expressed an issue with their vision before taking them for an eye exam, but according to Prevent Blindness America, 1 in 4 school-aged children in the United States has a vision problem, which if left untreated can affect learning ability, personality, and adjustments in school.
To view the multimedia release go to:
http://www.multivu.com/players/English/7938651-visionworks-lets-go-see-childrens-eye-health-awareness/
Kaléo, a privately-held pharmaceutical company, today announced the AUVI-Q® (epinephrine injection, USP) Auto-injector will be available by prescription starting February 14th, and announced AUVI-Q AffordAbility, a first-of-its-kind access program for AUVI-Q. Through this new program, patients with commercial insurance, even those with high-deductible plans, will have an out-of-pocket cost of $0. For patients who do not have government or commercial insurance, and have a household income of less than $100,000, AUVI-Q will be available free of charge. In addition, the cash price for AUVI-Q is $360 and will be available to those patients without government or commercial insurance. Each AUVI-Q prescription includes two Auto-injectors and one Trainer for AUVI-Q.
To view the multimedia release go to:
http://www.multivu.com/players/English/7981051-auvi-q-epinephrine-auto-injector-access-and-availability-launch/
